Safety and efficacy of danaparoid (Orgaran®) use in children

Acta Haematologica

Volumn 115, Issue 3-4, 2006, Pages 237-247

  Bidlingmaier, Christoph ^a   Magnani, Harry N ^c   Girisch, Monika ^b   Kurnik, Karin ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b University Hospital for Children and Adolescents   (Germany)

^c NV ORGANON   (Netherlands)

Author keywords

Danaparoid; Heparin induced thrombocytopenia, therapy

Indexed keywords

ALTEPLASE; ANTIBODY; DANAPAROID; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; UNCLASSIFIED DRUG; UROKINASE; XA ANTIBODY;

ADOLESCENT; ANTIBODY BLOOD LEVEL; BLEEDING; BOLUS INJECTION; CARDIOPULMONARY BYPASS; CARDIOVASCULAR SURGERY; CAUSE OF DEATH; CHILD; CLINICAL ARTICLE; CLINICAL EXAMINATION; CONTROLLED STUDY; DEATH; DRUG CROSS REACTIVITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TARGETING; FEMALE; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; INFANT; LUNG HEMORRHAGE; MALE; PEDIATRICS; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SEROLOGY; SURVIVAL RATE; THROMBOSIS; TREATMENT DURATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; CHONDROITIN SULFATES; DERMATAN SULFATE; DRUG EVALUATION; FIBRINOLYTIC AGENTS; HEMORRHAGE; HEPARIN; HEPARITIN SULFATE; HUMANS; INFANT; INFANT, NEWBORN; MALE; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RISK FACTORS; THROMBOSIS;

EID: 33645116989     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000090941     Document Type: Review

References (41)

1. Magnani HN: Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with orgaran (Org 10172). Thromb Haemost 1993;70:554-561.
2. Magnani HN: Orgaran (danaparoid) use in the syndrome of heparin-induced thrombocytopenia. Platelets 1997;8:74-81.
3. Risch L, Fischer JE, Herklotz R, Huber AR: Heparin-induced thrombocytopenia in paediatrics: clinical characteristics, therapy and outcome. Intensive Care Med 2004;30:1615-1624.
4. Warkentin TE: Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol 2003;121:535-555.
5. Warkentin TE, Roberts RS, Hirsh J, Kelton JG: An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch Intern Med 2003;163:2815-2824.
6. Schmugge M, Risch L, Huber AR, Benn A, Fischer JE: Heparin-induced thrombocytopenia-associated thrombosis in pediatric intensive care patients. Pediatrics 2002;109:E10.
7. Klenner AF, Greinacher A: Heparin-induced thrombocytopenia in children: in Warkentin TE, Greinacher A (eds): Heparin-induced Thrombocytopenia, ed 3. New York, Marcel Dekker, 2004, pp 553-571.
8. Chong BH, Castaldi PA: Heparin-induced thrombocytopenia: further studies of the effects of heparin-dependent antibodies on platelets. Br J Haematol 1986;64:347-354.
9. Greinacher A, Michels I, Mueller-Eckhardt C: Heparin-associated thrombocytopenia: successful therapy of patients after prospective selection of a compatible heparinoid with the heparin-induced platelet activation test (in German). Beitr Infusionsther 1992;30:408-412.
10. Amiral J, Bridey F, Wolf M, Boyer-Neumann C, Fressinaud E, Vissac AM, Peynaud-Debayle E, Dreyfus M, Meyer D: Antibodies to macromolecular platelet factor 4-heparin complexes in heparin-induced thrombocytopenia: a study of 44 cases. Thromb Haemost 1995;73:21-28.
11. Sheridan D, Carter C, Kelton JG: A diagnostic test for heparin-induced thrombocytopenia. Blood 1986;67:27-30.
12. Girisch M, Buheitel G, Ries M, Klinge J: Safe and effective use of danaparoid during cardiac catheterization in a 14 month old boy with tetralogy of Fallot and heparin-induced thrombocytopenia (abstract 68). Ann Hematol 2001; 80(suppl):A20.
13. Teien AN, Lie M: Evaluation of an amidolytic heparin assay method: increased sensitivity by adding purified antithrombin III. Thromb Res 1977;10:399-410.
14. von Roth B, Herkenrath P, Krebber J, Anschütz K: Use of a new heparinoid as the sole anticoagulant in haemodialysis of paediatric patients (in German). Nieren Hochdruckkrankheiten 1985;14:164.
15. Barth KSA: Incidence of the Heparin-induced Thrombocytopenia at the Justus Liebig University Hospital (in German); MD thesis Justus Liebig University, Giessen, 1998.
16. Bocquet R, Blanot S, Dautzenberg MD, Pierre-Kahn A, Carli P: Antiphospholipid antibody syndrome in pediatric neurosurgery: a haemostasis problem (in French). Ann Fr Anesth Reanim 1999;18:991-995.
17. Klement D, Rammos S, von Kries R, Kirschke W, Kniemeyer HW, Greinacher A: Heparin as a cause of thrombus progression. Heparin-associated thrombocytopenia is an important differential diagnosis in paediatric patients even with normal platelet counts. Eur J Pediatr 1996;155:11-14.
18. Neuhaus TJ, Goetschel P, Schmugge M, Leumann E: Heparin-induced thrombocytopenia type II on haemodialysis: switch to danaparoid. Pediatr Nephrol 2000;14:713-716.
19. Schiffmann H, Unterhalt M, Harms K, Figulla HR, Völpel H, Greinacher A: Successful treatment of heparin-induced thrombocytopenia (HIT) type II in childhood with recombinant hirudin (in German). Monatsschr Kinderheilkd 1997;145:606-612.
20. Sauer M, Gruhn B, Fuchs D, Altermann W, Zintl F: Heparin-induced thrombocytopenia type II during high-dose chemotherapy with stem-cell-rescue (in German). Klin Pädiatr 1998;210:102-105.
21. Weigel B, Laskey A, Krishnamurti L, Perentesis J, Neglia J, Foker J, Key N, Edson R, Steiner M: Danaparoid (orgaran) anticoagulation of pediatric patients with heparin-induced thrombocytopenia. J Pediatr Hematol Oncol 1999;321:327.
22. Wilhelm MJ, Schmid C, Kececioglu D, Mollhoff T, Ostermann H, Scheld HH: Cardiopulmonary bypass in patients with heparin-induced thrombocytopenia using Org 10172. Ann Thorac Surg 1996;61:920-924.
23. Zöhrer B, Zenz W, Rettenbacher A, Covi P, Kurnik K, Kroll H, Grubbauer HM, Muntean W: Danaparoid sodium (Orgaran) in four children with heparin-induced thrombocytopenia type II. Acta Paediatr 2001;90:765-771.
24. Nguyen TN, Gal P, Ransom JL, Carlos R: Lepirudin use in a neonate with heparin-induced thrombocytopenia. Ann Pharmacother 2003;37:229-233.
25. Ranze O, Rakow A, Ranze P, Eichler P, Greinacher A, Fusch C: Low-dose danaparoid sodium catheter flushes in an intensive care infant suffering from heparin-induced thrombocytopenia. Pediatr Crit Care Med 2001;2:175-177.
26. Lischetzki G, Dittrich K, Topf H-G, Klinge J: Pediatric heparin-induced thrombocytopenia type II on haemodialysis (abstract P38). Haemostaseologie 2004;24:A48.
27. Newall F, Barnes C, Ignjatovic V, Monagle P: Heparin-induced thrombocytopenia in children. J Paediatr Child Health 2003;39:289-292.
28. Saxon BR, Black MD, Edgell D, Noel D, Leaker MT: Pediatric heparin-induced thrombocytopenia: management with danaparoid (Orgaran). Ann Thorac Surg 1999;68:1076-1078.
29. Klenner AF, Lubenow N, Raschke R, Greinacher A: Heparin-induced thrombocytopenia in children: 12 new cases and a review of the literature. Thromb Haemost 2004;91:719-724.
30. Ranze O, Ranze P, Magnani HN, Greinacher A: Heparin-induced thrombocytopenia in paediatric patients: a review of the literature and a new case treated with danaparoid sodium. Eur J Paediatr 1999;158(suppl 3):S130-S133.
31. Spinler SA, Dager W: Overview of heparin-induced thrombocytopenia. Am J Health Syst Pharm 2003;60:S5-S11.
32. Smythe M: A comparison of argatroban and lepirudin outcomes (abstract). Thromb Haemost 2003;1(suppl 1):P2041.
33. Warkentin TE: Platelet count monitoring and laboratory testing for heparin-induced thrombocytopenia. Arch Pathol Lab Med 2002;126;1415-1423.
34. Donovan PC: Heparin-induced thrombocytopenia: strategies for identification and treatment. Clin Rev 2001;11:93-105.
35. Warkentin TE: Clinical picture of HIT; in Warkentin TE, Greinacher A (eds): Heparin-induced Thrombocytopenia, ed 3. New York, Marcel Dekker, 2004, pp 53-106.
36. Warkentin TE, Greinacher A: Heparin-induced thrombocytopenia and cardiac surgery. Ann Thorac Surg 2003;76:2121-2131.
37. Greinacher A, Lubenow N, Hinz P, Ekkernkamp A: Heparin-induced thrombocytopenia (in German). Dtsch Ärztebl 2003;100:2220-2229.
38. Albisetti M, Andrew M: Low molecular weight heparin in children. Eur J Pediatr 2002;161:71-77.
39. Greinacher A, Warkentin TW: Treatment of heparin-induced thrombocytopenia; in Warkentin TE, Greinacher A (eds): Heparin-induced Thrombocytopenia, ed 3. New York, Marcel Dekker, 2004, pp 335-370.
40. Ranze O, Greinacher A: Current treatment concepts in heparin-induced thrombocytopenia (in German). Dtsch Med Wochenschr 1999;124:865-873.
41. Monagle P, Michelson AD, Bovill E, Andrew M: Antithrombotic therapy in children. Chest 2001;119(1 suppl):344S-370S.